<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1633">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139901</url>
  </required_header>
  <id_info>
    <org_study_id>DTS_pulmosyme</org_study_id>
    <nct_id>NCT05139901</nct_id>
  </id_info>
  <brief_title>Usefulness of DORNASE in COVID-19 on HFNO</brief_title>
  <official_title>Usefulness of DORNASE (Pulmozyme®) in Patients With COVID-19 Respiratory Insufficiency on High-Flow Oxygen Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 pneumonia manifests among others with a thick bronhial secretion. It contains an&#xD;
      increased number of neutrophil extracellular traps (NETs), formed during netosis. DNA is a&#xD;
      major component in NETs. DNAse I (Pulmozyme®, Roche) is a recombinant human enzyme,&#xD;
      registered for inhalations in patients with Cystic fibrosis, in which NETs are also a typical&#xD;
      characteristic. DNAse I inhalations are typically well tolerated and with no major side&#xD;
      effects. Some initial reports exist of using DNAse I inhalations in COVID-19 patients, that&#xD;
      had benefitial effects. There are some trials registered with ClinicalTrials, investigating&#xD;
      the usufulness of DNAse I in intubated patients, but we have no knowledge of a trial,&#xD;
      investigating the usufulness of this drug in patients receiving High Flow Nasal Oxygen&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind randomised</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intubations</measure>
    <time_frame>7 days</time_frame>
    <description>Number of intubations necessary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PaO2/FiO2</measure>
    <time_frame>7 days</time_frame>
    <description>Increase in PaO2/FiO2 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflamation</measure>
    <time_frame>7 days</time_frame>
    <description>Reduction of inflamation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>4% saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4% Saline inhalations twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmosyme</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DNAse alpha inhalations twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>inhalations</intervention_name>
    <description>inhalations twice daily</description>
    <arm_group_label>4% saline</arm_group_label>
    <arm_group_label>Pulmosyme</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive SARS-CoV-2 RNA PCR swab&#xD;
&#xD;
          -  inflamatory phase of infection&#xD;
&#xD;
          -  HFNO&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  previous treatment with DNAse alfa&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marko ŽLIČAR</last_name>
    <phone>+38615224553</phone>
    <email>marko.zlicar@kclj.si</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Marko Zlicar</investigator_full_name>
    <investigator_title>MD, PhD, DESA</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

